Search

Your search keyword '"Shiku, Hiroshi"' showing total 1,465 results
Start Over Author "Shiku, Hiroshi"
1,465 results on '"Shiku, Hiroshi"'

152. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients

Author

Kawabata, Ryohei, Wada, Hisashi, Isobe, Midori, Saika, Takashi, Sato, Shuichiro, Uenaka, Akiko, Miyata, Hiroshi, Yasuda, Takushi, Doki, Yuichiro, Noguchi, Yuji, Kumon, Hiromi, Tsuji, Kazuhide, Iwatsuki, Keiji, Shiku, Hiroshi, Ritter, Gerd, Murphy, Roger, Hoffman, Eric, Old, Lloyd J., Monden, Morito, and Nakayama, Eiichi

Published
2007
Full Text
View/download PDF

171. Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2, 8-sialyltransferase cDNA using anti-GD2 monoclonal antibody

Author

Haraguchi, Masashi, Yamashiro, Shuji, Yamamoto, Akihito, Furukawa, Keiko, Takamiya, Kogo, Lloyd, Kenneth O., Shiku, Hiroshi, and Furukawa, Koichi

Subjects
Circular DNA -- Research, Monoclonal antibodies -- Research, Cloning -- Observations, Science and technology
Abstract

Use of an expression cloning method for deriving GM3 alpha-2,8-sialyltransferase cDNA with the help of an anti-GD2 monoclonal antibody facilitates the isolation of a GD3 synthase gene from a host recipient cell line, KF 3027-Hyg5. The cDNA clones of the gene consist of an open reading frame and a 1650-bp region, with the amino acid sequence containing catalytic, transmembrane and cytoplasmic domains. The sequence also expresses a sialyl motif homologous to that in other sialyltransferases. Human melanoma lines contain strong GD3 synthase mRNA expressions.

Published
1994

174. Hemostatic Abnormalities Following Bone Marrow Transplantation

Author

Tamaki, Shigehisa, Wada, Hideo, Ohfuzi, Kazuya, Shibata, Takeshi, Masuya, Masahiro, Kageyama, Shinichi, Gabazza, Esteban C., Kawakami, Keiki, Tsuji, Kohta, Miyanishi, Eiki, Minami, Nobuyuki, Nobori, Tsutomu, and Shiku, Hiroshi

Published
2002

175. GD2 ganglioside on human T-lymphotropic virus type I-infected T cells: possible activation of beta-1,4-N-acetylgalactosaminyltransferase gene by p40-tax

Author

Furukawa, Keiko, Akagi, Tsuyoshi, Nagata, Yasuhiko, Yamada, Yasuaki, Kunitada, Shimotohno, Cheung, Nai-Kong V., Shiku, Hiroshi, and Furukawa, Koichi

Subjects
Gangliosides -- Physiological aspects, Leukemia -- Physiological aspects, Lymphocytes -- Research, Science and technology
Abstract

The ganglioside expression of various human leukemia lines and uncultured or short-term cultured leukemia cells from patients were investigated. The resultsshowed that GD2 ganglioside is highly and specifically expressed in human T-cell lymphotropic type I-infected T-cells and in adult T-cell leukemia cells.This pattern of GD2 expression correlated with the expression of p40-tax and beta-1,4-N-acetylgalactosaminyltransferase (GM2/GD2 synthase). It is proposed that GD2 is synthesized by the action of p40-tax-induced GM2/GD2 synthase.

Published
1993

193. Phase I/II clinical trial of NY-ESO-1-specific TCR-engineered T-cell transfer combined with a novel T-cell stimulator CHP:NE1 for patients with refractory soft tissue sarcoma.

Author

Ishihara, Mikiya, primary, Hattori, Hiroyoshi, additional, Arai, Eisuke, additional, Nishida, Yoshihiro, additional, Takada, Kohichi, additional, Emori, Makoto, additional, Kawai, Akira, additional, Ueda, Takafumi, additional, Endo, Makoto, additional, Matsumoto, Yoshihiro, additional, Sasada, Tetsuro, additional, Sato, Eiichi, additional, Yamada, Tomomi, additional, Matsumine, Akihiko, additional, Nagata, Yasuhiro, additional, Harada, Naozumi, additional, Shiku, Hiroshi, additional, and Kageyama, Shinichi, additional

Published
2019
Full Text
View/download PDF

194. Tumor responses and early onset cytokine release syndrome in synovial sarcoma patients treated with a novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer.

Author

Ishihara, Mikiya, primary, Kitano, Shigehisa, additional, Hattori, Hiroyoshi, additional, Miyahara, Yoshihiro, additional, Kato, Hidefumi, additional, Mishima, Hideyuki, additional, Yamamoto, Noboru, additional, Funakoshi, Takeru, additional, Kojima, Takashi, additional, Sasada, Tetsuro, additional, Sato, Eiichi, additional, Okamoto, Sachiko, additional, Tomura, Daisuke, additional, Chono, Hideto, additional, Nukaya, Ikuei, additional, Mineno, Junichi, additional, Ikeda, Hiroaki, additional, Watanabe, Takashi, additional, Kageyama, Shinichi, additional, and Shiku, Hiroshi, additional

Published
2019
Full Text
View/download PDF

195. Presentation of a major histocompatibility complex class 1–binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide–truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy

Author

Ikuta, Yasushi, Katayama, Naoyuki, Wang, Lijie, Okugawa, Toshiharu, Takahashi, Yoshiyuki, Schmitt, Michael, Gu, Xiaogang, Watanabe, Masato, Akiyoshi, Kazunari, Nakamura, Hideo, Kuribayashi, Kagemasa, Sunamoto, Junzo, and Shiku, Hiroshi

Published
2002
Full Text
View/download PDF

197. Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology

Author

Rivoltini Licia, Ribas Antoni, Pos Zoltan, Petricoin Emanuel F, Palucka A Karolina, Nishikawa Hiroyoshi, Nakamura Kiminori, Mayrand-Chung Shawmarie, Masucci Giuseppe, Matsubara Hisahiro, Malyguine Anatoli, Maio Michele, Lotze Michael T, Liotta Lance, Lehmann Paul V, Kleen Thomas O, Kirkwood John M, Kawakami Yutaka, Kato Kazunori, Kashani-Sabet Mohammed, Kanamoto Akira, Jinushi Masahisa, Jacobson James, Hirohashi Yoshihiko, Imai Kohzoh, Fridman Wolf, Eremin Oleg, Doki Yuichiro, Chaussabel Damien, Akutsu Yasunori, Ambs Stefan, Wigginton Jon M, Lee Peter P, Khleif Samir N, Fox Bernard A, Disis Mary L, Butterfield Lisa H, Wang Ena, Thurin Magdalena, Sato Marimo, Tahara Hideaki, Sato Noriyuki, Shiku Hiroshi, Slingluff Craig L, Streicher Howard, Stroncek David F, Takeuchi Hiroya, Toyota Minoru, Wada Hisashi, Wu Xifeng, Wulfkuhle Julia, Yaguchi Tomonori, Zeskind Benjamin, Zhao Yingdong, Zocca Mai-Britt, and Marincola Francesco M

Subjects
Medicine
Abstract

Abstract Supported by the Office of International Affairs, National Cancer Institute (NCI), the "US-Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009. The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy. The effort will culminate on October 28th 2009 in the "iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", which will be held in Washington DC in association with the Annual Meeting. The purposes of the US-Japan workshop were a) to discuss novel approaches to enhance the discovery of predictive and/or prognostic markers in cancer immunotherapy; b) to define the state of the science in biomarker discovery and validation. The participation of Japanese and US scientists provided the opportunity to identify shared or discordant themes across the distinct immune genetic background and the diverse prevalence of disease between the two Nations. Converging concepts were identified: enhanced knowledge of interferon-related pathways was found to be central to the understanding of immune-mediated tissue-specific destruction (TSD) of which tumor rejection is a representative facet. Although the expression of interferon-stimulated genes (ISGs) likely mediates the inflammatory process leading to tumor rejection, it is insufficient by itself and the associated mechanisms need to be identified. It is likely that adaptive immune responses play a broader role in tumor rejection than those strictly related to their antigen-specificity; likely, their primary role is to trigger an acute and tissue-specific inflammatory response at the tumor site that leads to rejection upon recruitment of additional innate and adaptive immune mechanisms. Other candidate systemic and/or tissue-specific biomarkers were recognized that might be added to the list of known entities applicable in immunotherapy trials. The need for a systematic approach to biomarker discovery that takes advantage of powerful high-throughput technologies was recognized; it was clear from the current state of the science that immunotherapy is still in a discovery phase and only a few of the current biomarkers warrant extensive validation. It was, finally, clear that, while current technologies have almost limitless potential, inadequate study design, limited standardization and cross-validation among laboratories and suboptimal comparability of data remain major road blocks. The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results